title: Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemia.
authors.affiliation: Department of Pathology, Academic Medical Center, University of Amsterdam, The Netherlands.
authors.forename: Martin F M
authors.initials: MF
authors.lastname: de Rooij
authors.affiliation: Department of Pathology, Academic Medical Center, University of Amsterdam, The Netherlands.
authors.forename: Annemieke
authors.initials: A
authors.lastname: Kuil
authors.affiliation: Department of Pathology, Academic Medical Center, University of Amsterdam, The Netherlands.
authors.forename: Willem
authors.initials: W
authors.lastname: Kraan
authors.affiliation: Deptartment of Hematology, Academic Medical Center, University of Amsterdam, The Netherlands Lymphoma and Myeloma Center Amsterdam - LYMMCARE, The Netherlands.
authors.forename: Marie José
authors.initials: MJ
authors.lastname: Kersten
authors.affiliation: Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: Steven P
authors.initials: SP
authors.lastname: Treon
authors.affiliation: Department of Pathology, Academic Medical Center, University of Amsterdam, The Netherlands Lymphoma and Myeloma Center Amsterdam - LYMMCARE, The Netherlands.
authors.forename: Steven T
authors.initials: ST
authors.lastname: Pals
authors.affiliation: Department of Pathology, Academic Medical Center, University of Amsterdam, The Netherlands Lymphoma and Myeloma Center Amsterdam - LYMMCARE, The Netherlands marcel.spaargaren@amc.uva.nl.
authors.forename: Marcel
authors.initials: M
authors.lastname: Spaargaren
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000077329:Agammaglobulinaemia Tyrosine Kinase; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002448:Cell Adhesion / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D054377:Chemokine CXCL12 / Q000235:genetics / Q000276:immunology; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D039041:Integrin alpha4beta1 / Q000235:genetics / Q000276:immunology; D058990:Molecular Targeted Therapy; D053594:Myeloid Differentiation Factor 88 / Q000235:genetics / Q000276:immunology; D010880:Piperidines; D010950:Plasma Cells / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D011505:Protein-Tyrosine Kinases / Q000235:genetics / Q000276:immunology; D011687:Purines / Q000494:pharmacology*; D011720:Pyrazoles / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*; D052999:Quinazolinones / Q000494:pharmacology*; D011947:Receptors, Antigen, B-Cell / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000276:immunology; D019718:Receptors, CXCR4 / Q000235:genetics / Q000276:immunology; D015398:Signal Transduction; D019010:Vascular Cell Adhesion Molecule-1 / Q000235:genetics / Q000276:immunology; D008258:Waldenstrom Macroglobulinemia / Q000235:genetics / Q000276:immunology / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; C515255:CXCL12 protein, human; C527276:CXCR4 protein, human; D054377:Chemokine CXCL12; D039041:Integrin alpha4beta1; C507779:MYD88 protein, human; D053594:Myeloid Differentiation Factor 88; D010880:Piperidines; D011687:Purines; D011720:Pyrazoles; D011743:Pyrimidines; D052999:Quinazolinones; D011947:Receptors, Antigen, B-Cell; D019718:Receptors, CXCR4; D019010:Vascular Cell Adhesion Molecule-1; C551803:ibrutinib; D011505:Protein-Tyrosine Kinases; D000077329:Agammaglobulinaemia Tyrosine Kinase; D000225:Adenine; C552946:idelalisib
keywords: BCR; CXCR4; Waldenström macroglobulinemia; adhesion; kinase inhibitors